Compare Archer Aviation Inc (ACHR) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Archer Aviation IncTrade

BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs BridgeBio Pharma Inc — how do they compare? Archer Aviation Inc trades at $6.92 (market cap $5.23B), while BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B). The key difference: BridgeBio Pharma Inc is far larger — about 3.1× Archer Aviation Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.

	ACHR	BBIO
Market Cap	$5.23B	$16.36B
Sector	Industrials	Health
52-Week High	$13.64	$90.17
52-Week Low	$4.44	$47.29
Enterprise Value	$3.79B	$18.14B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

No Aura AI signal available yet.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACHR

Archer Aviation nears commercialization with strong growth and undervalued stock despite recent gainsSeeking Alpha · 22 hours agoBullish Archer Aviation stock jumps 11% on Boeing deal details and strong Q2 revenue growth24/7 Wall Street · 1 day agoBullish Red Cat shares jump 6.84% post-earnings despite revenue miss, driven by strong growth and sector momentum.24/7 Wall Street · 1 day agoBullish View details →

BBIO

BridgeBio beats Q2 estimates, confirms $1B+ 2026 sales goal and plans three product launches by 2027.Seeking Alpha · 1 day agoBullish View details →

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.